bluuebunny/crossref_metadata_2025_split huggingface dataset:
Temporary abdominal packing for management of persistent hemorrhage after liver lobectomy in three dogs with hepatic neoplasia
Authors: Evans Natashia A. , Hardie Robert J. , Walker Julie , Bach Jonathan 
Published: August 2019

AbstractObjectiveTo describe the technique and outcome of temporary abdominal packing for control of persistent hemorrhage from liver lobectomy sites in 3 dogs with hepatic neoplasia.Series SummaryThree dogs were treated with massive transfusion for hemoperitoneum secondary to bleeding hepatic tumors. Surgical resection of the affected liver lobe(s) was performed but hemostasis could not be achieved through conventional methods. All 3 dogs demonstrated acidosis, hypothermia, and coagulopathy. Temporary abdominal packing of liver lobectomy sites was performed and hemostasis was achieved in all dogs. One dog died prior to removal of the packing. The other 2 dogs had the packing removed with no evidence of rebleeding. One dog was euthanized after removal of the packing due to acute kidney injury and the remaining dog survived to discharge.New or Unique Information ProvidedTemporary abdominal packing combined with medical management was successful in achieving hemostasis in all 3 dogs, however, 2 dogs died of complications related to multiple organ dysfunction syndrome. Temporary abdominal packing may be considered when definitive surgical hemostasis cannot be achieved or in unstable patients not able to tolerate prolonged surgical times. Further research is needed to better define efficacy, optimal patient selection, packing technique, timing of removal, and complications associated with temporary abdominal packing.
Successful management of acute bilirubin encephalopathy in a dog with immune‐mediated hemolytic anemia using therapeutic plasma exchange
Authors: Heffner Geoff G. , Cavanagh Amanda , Nolan Benjamin 
Published: August 2019

AbstractObjectiveTo describe the successful management of acute bilirubin encephalopathy in a dog with immune‐mediated hemolytic anemia (IMHA) treated with therapeutic plasma exchange (TPE) in conjunction with conventional medical management.Case SummaryA 6‐year‐old neutered male Australian Cattle Dog diagnosed with IMHA developed severe hyperbilirubinemia and stupor within the first 48 hours of implementing immunosuppressive therapy consisting of corticosteroids and mycophenolate. The patient received 4 blood transfusions during this period, but remained severely anemic PCV (18%) and experienced a subsequent increase in total bilirubin from 78 µmol/L (4.6 mg/dL) to a peak value of 1,563 µmol/L (91.4 mg/dL). The patient's neurological status rapidly deteriorated, resulting in lateral recumbency, vertical nystagmus, extensor rigidity, and stuporous mentation. Over the next 3 days, TPE was provided once every 24 hours, decreasing serum bilirubin, immunoglobulin G (IgG), and immunoglobulin M (IgM). The patient's red blood cell (RBC) transfusion requirements decreased immediately, requiring only 1 transfusion over the next 7 days that was required due to procedure‐associated blood loss. Gradual neurological improvement was noted as serum bilirubin decreased. A brain magnetic resonance imaging (MRI) did not reveal any structural abnormalities and the patient was discharged after 11 days of hospitalization. Following discharge, the patient had complete remission of IMHA without any residual neurological deficits. Therapeutic plasma exchange played an integral role in case management and was successful in reducing bilirubin, IgG, and IgM.New or Unique Information ProvidedBilirubin encephalopathy has been rarely reported in small animal medicine and cases have been limited to postmortem documentation. This is the first suspected case of acute bilirubin encephalopathy in a dog that survived and describes the clinical course of disease. The kinetics of serum bilirubin, IgG, and IgM concentrations before and after TPE and throughout the hospitalization period are also described.
Inhibition of CaCO3 growth in hard water by quercetin as green inhibitor
Authors: Ghizellaoui Samira , Boumagoura Manel , Rhouati Salah , Cheap‐Charpentier Hélène , Horner Olivier 
Published: August 2019

AbstractIn this study, the properties of quercetin (3,3′,4′,5,7‐pentahydroxyflavone) solution towards CaCO3 formation were evaluated by using chronoamperometry (CA) and impedance measurements. Quercetin a flavonoid present in plants as a secondary metabolite. Using CA, precipitation of CaCO3 was totally inhibited by adding 2 mg/L of quercetin (T = 30°C). The same result was obtained by impedance measurements. Scanning electron microscopy (SEM) and X‐ray diffraction (XRD) were used to characterize the calcium carbonate scale without or with quercetin treatment. The predominant crystalline structure corresponds to a mixture of calcite and aragonite.
Job type and other socio-demographic factors associated with participation in a national, cross-sectional study of Danish employees
Authors: Johnsen Nina Føns , Thomsen Birthe Lykke , Hansen Jørgen Vinsløv , Christensen Birgitte Schütt , Rugulies Reiner , Schlünssen Vivi 
Published: August 2019

ObjectivesParticipation in population-based surveys and epidemiological studies has been declining over the years in many countries. The aim of this study was to examine the association between job type and participation in the work environment and health in Denmark survey with/without taking into account other socio-demographic factors.DesignCross-sectional survey using questionnaire data on working environment and registry data on job type, industry and socio-economic variables.SettingThe work environment and health study.ParticipantsA total of 50 806 employees (15 767 in a stratified workplace sample; 35 039 in a random sample) working at least 35 hours/month and earning at least 3000 Danish Krones.Outcome measuresThe outcome was participation (yes/no) and logistic regression was used to estimate the OR for participation with 95% CI.ResultsIn the random sample, women were more likely to participate than men, and married/non-married couples were more likely to participate than persons living alone or more families living together. Participation increased with higher age, higher annual personal income, higher education and Danish origin, and there were marked differences in participation between job types and geographical regions. For armed forces, craft and related trade workers, and skilled agricultural, forestry and fishery workers, the association between job type and participation was strongly attenuated after adjustment for sex and age. Additional adjustment for annual income, education, cohabitation, country of origin and geographical region generally attenuated the association between job type and participation. Similar results were found in the stratified workplace sample.ConclusionIn this population of Danish employees, participation varied across types of jobs. Some but not all the variation between job types was explained by other socio-demographic factors. Future studies using questionnaires may consider targeting efforts to (sub-)populations, defined by job type and other factors, where response probability is particularly important.
Relationship between metabolic syndrome and its components and cardiovascular disease in middle-aged and elderly Chinese population: a national cross-sectional survey
Authors: Li Wenzhen , Song Fujian , Wang Xiaojun , Wang Dongming , Chen Dajie , Yue Wei , Zhang Hong , Wang Zhihong , Lu Zuxun 
Published: August 2019

ObjectivesTo assess the relationship between metabolic syndrome (MetS) and its components and cardiovascular disease (CVD) according to different criteria of MetS, as well as whether the estimated association between MetS and CVD was affected by different definitions of MetS among the Chinese population.DesignPopulation-based, cross-sectional study.SettingData were from a large-scale national stroke screening survey, China National Stroke Screening and Prevention Project.ParticipantsA nationally representative sample of 109 551 Chinese adults aged ≥40 years in 2014–2015 were included.Primary outcome measuresCVD conditions (stroke, coronary heart disease (CHD) and atrial fibrillation (AF)) diagnosed by clinicians were self-reported.ResultsORs after adjusting for CHD, stroke, AF and CVD in those with MetS using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criterion were 1.56 (95% CI 1.48 to 1.63), 1.23 (95% CI 1.17 to 1.30), 1.14 (95% CI 1.08 to 1.21) and 1.40 (95% CI 1.35 to 1.45); 1.51 (95% CI 1.44 to 1.58), 1.20 (95% CI 1.14 to 1.26), 1.09 (95% CI 1.04 to 1.15) and 1.34 (95% CI 1.29 to 1.38) with the American Heart Association/National Heart, Lung, and Blood Institute criterion; and 1.41 (95% CI 1.35 to 1.48), 1.24 (95% CI 1.19 to 1.30), 1.12 (95% CI 1.06 to 1.18) and 1.31 (95% CI 1.27 to 1.35) with the International Diabetes Federation criterion, respectively. Elevated blood pressures were all highly related to the prevalence of stroke and AF, and reduced high-density lipoprotein-cholesterol was associated with a higher OR for CHD than other individual components of MetS.ConclusionsMetS is significantly associated with CVD, and the prevalence of CVD was more evident when MetS was defined according to the NCEP ATP III criterion. Developing effective public health strategies for the prevention, detection and treatment of MetS should be an urgent priority to reduce the burden of CVD in China.
Delivery room interventions to prevent bronchopulmonary dysplasia in preterm infants: a protocol for a systematic review and network meta-analysis
Authors: Mitra Souvik , Disher Timothy , Pichler Gerhard , D'Souza Brandon , Mccord Helen , Chayapathi Varsha , Jones Karlee , Schmölzer Georg 
Published: August 2019

IntroductionAs gestational age decreases, incidence of bronchopulmonary dysplasia (BPD) and chronic lung disease increases. There are many interventions used in the delivery room to prevent acute lung injury and consequently BPD in these patients. The availability of different treatment options often poses a practical challenge to the practicing neonatologist when it comes to making an evidence-based choice as the multitude of pairwise systematic reviews including Cochrane reviews that are currently available only provide a narrow perspective through head-to-head comparisons.Methods and analysisWe will conduct a systematic review of all randomised controlled trials evaluating delivery room interventions within the first golden hour after birth for prevention of BPD. The primary outcome includes BPD. Secondary outcomes include death at 36 weeks of postmenstrual age or before discharge; severe intraventricular haemorrhage (grade 3 or 4 based on the Papile criteria); any air leak syndromes (including pneumothorax or pulmonary interstitial emphysema); retinopathy of prematurity (any stage) and neurodevelopmental impairment at 18–24 months. We will search from their inception to August 2018, the following databases: Medline, EMBASE and Cochrane Central Register of Controlled Trials as well as grey literature resources. Two reviewers will independently screen titles and abstracts, review full texts, extract information and assess the risk of bias and the confidence in the estimate (with Grading of Recommendations Assessment, Development and Evaluation approach). This review will use Bayesian network meta-analysis approach which allows the comparison of the multiple delivery room interventions for prevention of BPD. We will perform a Bayesian network meta-analysis to combine the pooled direct and indirect treatment effect estimates for each outcome, effectiveness and safety of delivery room interventions for prevention of BPD.Ethics and disseminationThe proposed protocol is a network meta-analysis, which has been registered on PROSPERO International prospective register of systematic reviews (CRD42018078648). The results will provide an evidence-based guide to choosing the right sequence of early postnatal interventions that will be associated with the least likelihood of inducing lung injury and BPD in preterm infants. Furthermore, we will identify knowledge gaps and will encourage further research for other therapeutic options. Therefore, its results will be disseminated through peer-reviewed publications and conference presentations. Due to the nature of the design, no ethics approval is necessary.
Real-time navigation during hepatectomy using fusion indocyanine green-fluorescence imaging: protocol for a prospective cohort study
Authors: Gon Hidetoshi , Komatsu Shohei , Murakami Sae , Kido Masahiro , Tanaka Motofumi , Kuramitsu Kaori , Tsugawa Daisuke , Awazu Masahide , Toyama Hirochika , Fukumoto Takumi 
Published: August 2019

IntroductionIn-vivo fluorescence imaging techniques using indocyanine green (ICG) to identify liver tumours and hepatic segment boundaries have been recently developed. The purpose of this study is to evaluate the efficacy of fusion ICG-fluorescence imaging for navigation during hepatectomy.Methods and analysisThis will be an exploratory single-arm clinical trial; patients with liver tumours will undergo hepatectomy using the ICG-fluorescence imaging system. In total, 110 patients with liver tumours scheduled for elective hepatectomy will be included in this study. Preoperatively, ICG will be intravenously injected at a dose of 0.5 mg/kg body weight within 2 days. To detect liver tumours intraoperatively, the hepatic surface will be initially observed using the ICG-fluorescence imaging system. After identifying and clamping the portal pedicle corresponding to the hepatic segments, including the liver tumours to be resected, additional ICG will be injected intravenously at a dose of 0.5 mg/kg body weight to identify the boundaries of the hepatic segments. The primary outcome measure will be the success or failure of the ICG-fluorescence imaging system in identifying hepatic segments. The secondary outcomes will be the success or failure in identifying liver tumours, liver function indicators, operative time, blood loss, rate of postoperative complications and recurrence-free survival. The findings obtained through this study are expected to help to establish the utility of ICG-fluorescence imaging systems, and therefore contribute to prognostic outcome improvements in patients undergoing hepatectomy for various causes.Ethics and disseminationThe protocol has been approved by the Kobe University Clinical Research Ethical Committee. The findings of this study will be disseminated widely through peer-reviewed publications and conference presentations.Trial registration numberUMIN000031054 and jRCT1051180070
Beta-adrenergic blockade for attenuation of catecholamine surge after traumatic brain injury: a randomized pilot trial
Authors: Schroeppel Thomas J , Sharpe John P , Shahan Charles Patrick , Clement Lesley P , Magnotti Louis J. , Lee Marilyn , Muhlbauer Michael , Weinberg Jordan A , Tolley Elizabeth A , Croce Martin A , Fabian Timothy C 
Published: August 2019

BackgroundBeta-blockers have been proven in multiple studies to be beneficial in patients with traumatic brain injury. Few prospective studies have verified this and no randomized controlled trials. Additionally, most studies do not titrate the dose of beta-blockers to therapeutic effect. We hypothesize that propranolol titrated to effect will confer a survival benefit in patients with traumatic brain injury.MethodsA randomized controlled pilot trial was performed during a 24-month period. Patients with traumatic brain injury were randomized to propranolol or control group for a 14-day study period. Variables collected included demographics, injury severity, physiologic parameters, urinary catecholamines, and outcomes. Patients receiving propranolol were compared with the control group.ResultsOver the study period, 525 patients were screened, 26 were randomized, and 25 were analyzed. Overall, the mean age was 51.3 years and the majority were male with blunt mechanism. The mean Injury Severity Score was 21.8 and median head Abbreviated Injury Scale score was 4. Overall mortality was 20.0%. Mean arterial pressure was higher in the treatment arm as compared with control (p=0.021), but no other differences were found between the groups in demographics, severity of injury, severity of illness, physiologic parameters, or mortality (7.7% vs. 33%; p=0.109). No difference was detected over time in any variables with respect to treatment, urinary catecholamines, or physiologic parameters. Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment, and Acute Physiology and Chronic Health Evaluation scores all improved over time. GCS at study end was significantly higher in the treatment arm (11.7 vs. 8.9; p=0.044). Finally, no difference was detected with survival analysis over time between groups.ConclusionsDespite not being powered to show statistical differences between groups, GCS at study end was significantly improved in the treatment arm and mortality was improved although not at a traditional level of significance. The study protocol was safe and feasible to apply to an appropriately powered larger multicenter study.Level of evidenceLevel 2—therapeutic.
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Authors: Maron Steven B. , Chase Leah M. , Lomnicki Samantha , Kochanny Sara , Moore Kelly L. , Joshi Smita S. , Landron Stacie , Johnson Julie , Kiedrowski Lesli A. , Nagy Rebecca J. , Lanman Richard B. , Kim Seung Tae , Lee Jeeyun , Catenacci Daniel V.T. 
Published: August 2019

Abstract

Purpose:
Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic options. Utilizing a 73-gene plasma-based next-generation sequencing (NGS) cell-free circulating tumor DNA (ctDNA-NGS) test, we sought to evaluate the role of ctDNA-NGS in guiding clinical decision-making in GEA.

Experimental Design:
We evaluated a large cohort (n = 2,140 tests; 1,630 patients) of ctDNA-NGS results (including 369 clinically annotated patients). Patients were assessed for genomic alteration (GA) distribution and correlation with clinicopathologic characteristics and outcomes.

Results:
Treatment history, tumor site, and disease burden dictated tumor-DNA shedding and consequent ctDNA-NGS maximum somatic variant allele frequency. Patients with locally advanced disease having detectable ctDNA postoperatively experienced inferior median disease-free survival (P = 0.03). The genomic landscape was similar but not identical to tissue-NGS, reflecting temporospatial molecular heterogeneity, with some targetable GAs identified at higher frequency via ctDNA-NGS compared with previous primary tumor-NGS cohorts. Patients with known microsatellite instability-high (MSI-High) tumors were robustly detected with ctDNA-NGS. Predictive biomarker assessment was optimized by incorporating tissue-NGS and ctDNA-NGS assessment in a complementary manner. HER2 inhibition demonstrated a profound survival benefit in HER2-amplified patients by ctDNA-NGS and/or tissue-NGS (median overall survival, 26.3 vs. 7.4 months; P = 0.002), as did EGFR inhibition in EGFR-amplified patients (median overall survival, 21.1 vs. 14.4 months; P = 0.01).

Conclusions:
ctDNA-NGS characterized GEA molecular heterogeneity and rendered important prognostic and predictive information, complementary to tissue-NGS.
See related commentary by Frankell and Smyth, p. 6893
STAT3 Targets ERR-α to Promote Epithelial–Mesenchymal Transition, Migration, and Invasion in Triple-Negative Breast Cancer Cells
Authors: Ma Jia-Hui , Qi Jie , Lin Shi-Qi , Zhang Cai-Yun , Liu Fang-yuan , Xie Wei-Dong , Li Xia 
Published: August 2019

Abstract

STAT3 is constitutively activated in many malignant tumor types and plays an important role in multiple aspects of cancer aggressiveness. In this study, we found that estrogen-related receptor α (ERR-α) correlating with STAT3 was highly expressed in triple-negative breast cancer (TNBC) cell lines and tissues, which was associated with both the pathologic stage and prognosis of patients with TNBC. In vitro studies showed that ERR-α promoted TNBC cell migration and invasion, which was regulated by STAT3. Phosphorylated STAT3 (p-STAT3, Tyr 705) could bind to the promotor of ERR-α, and activate its transcription, which was suggested by luciferase assay and chromatin immunoprecipitation assay. We also found that ERR-α was the key target gene regulated by STAT3 in promoting epithelial–mesenchymal transition (EMT), migration, and invasion. ERR-α upregulated the expression of ZEB1, N-cadherin, and vimentin while downregulated the expression of E-cadherin. Furthermore, in vivo studies showed that ERR-α could increase the metastasis ability of TNBC. Our finding demonstrated that ERR-α was a direct regulatory gene target of p-STAT3, which was enriched for processes involving invasion and metastasis in TNBC and provided insight into TNBC pathogenesis, as well as a potential therapeutic option against TNBC metastasis.

Implications:
Our research first showed that p-STAT3 (Tyr 705) could bind to the promotor region of ERR-α and promote EMT in TNBC by ZEB1 pathways, thus providing a potential clinical target for TNBC.
Association of Smoking Status With Long‐Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
Authors: Qintar Mohammed , Li Zhuokai , Vemulapalli Sreekanth , Chhatriwalla Adnan K. , Baron Suzanne J. , Kosinski Andrzej S. , Saxon John T. , Spertus John A. , Cohen David J. , Arnold Suzanne V. 
Published: August 2019

Background

Smoking is a significant risk factor for aortic stenosis but its impact on clinical and health status outcomes after transcatheter aortic valve replacement (
TAVR
) has not been described.

Methods and Results

Patients (n=72 165) undergoing
TAVR
at 457
US
sites in the STS/
ACC TVT
(Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) Registry between November 2011 and June 2016 were categorized at the time of
TAVR
as current/recent smokers versus prior/nonsmokers. A series of multivariable models examined the association between smoking status and outcomes, including 1‐year mortality, rehospitalization, mean gradient, and health status (measured by the 12‐item Kansas City Cardiomyopathy Questionnaire–Overall Summary Score [
KCCQ
‐
OS
]) and in‐hospital outcomes. A total of 4063 patients (5.6%) were smokers. Smokers presented for
TAVR
at a younger age (75 [68–81] years versus 83 [77–88] years) but with a greater burden of cardiovascular and lung disease. In adjusted models, smoking was associated with lower in‐hospital mortality (relative risk, 0.74; 95%
CI
, 0.62–0.89 [
P
=0.001]) but not with in‐hospital stroke/transient ischemic attack or myocardial infarction. Smoking status had no association with postdischarge mortality, stroke, myocardial infarction, or heart failure (HF) but was associated with slightly lower 1‐year
KCCQ
‐
OS
scores (2.4‐point lower
KCCQ
‐
OS
; 95%
CI
, −4.6 to −0.2 [
P
=0.031]) and higher mean aortic valve gradients (11.1 versus 10.2 mm Hg,
P
<0.001) in adjusted models.

Conclusions

The current/recent smoking rate in
US
patients with TAVR is 5.6% and smokers present at a younger age for
TAVR
. Smoking was associated with lower in‐hospital but similar long‐term survival after
TAVR
, slightly worse long‐term health status, and marginally higher mean aortic valve gradients. Further research is needed to understand the effect of smoking cessation on outcomes.